GLENMEDE TRUST CO NA: MKL position timeline
Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of GLENMEDE TRUST CO NA on MKL, newest first. How the timeline and the estimate are built.
GLENMEDE TRUST CO NA held 186 MKL shares at 2026-06-30 per its 13F-HR filed 2026-08-10.
the latest 13F is the newest step
- period ended2026-06-3013F 186 sharesChange vs previous 13F -6 shares
<0.01% of the 13F portfolio, value $363,259.
13F-HR 0001398344-26-013895 filed by GLENMEDE TRUST CO NA
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2026-03-3113F 192 sharesChange vs previous 13F -6 shares
<0.01% of the 13F portfolio, value $367,501.
13F-HR 0001398344-26-009724 filed by GLENMEDE TRUST CO NA
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-12-3113F 198 sharesChange vs previous 13F +15 shares
<0.01% of the 13F portfolio, value $425,630.
13F-HR 0001398344-26-003230 filed by GLENMEDE TRUST CO NA
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-03-3113F 183 sharesChange vs previous 13F -63 shares
<0.01% of the 13F portfolio, value $342,138.
13F-HR 0001398344-25-009609 filed by GLENMEDE TRUST CO NA
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2024-12-3113F 246 sharesChange vs previous 13F -52 shares
<0.01% of the 13F portfolio, value $424,652.
13F-HR 0001398344-25-002875 filed by GLENMEDE TRUST CO NA
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2024-09-3013F 298 sharesChange vs previous 13F not available
<0.01% of the 13F portfolio, value $467,436.
13F-HR 0001398344-24-020665 filed by GLENMEDE TRUST CO NA
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).